p53 as a target for anti-cancer drug development.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2006-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.CRITREVONC.2005.10.005PMID 16690321
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeted gene therapy for breast cancer with truncated Bid

  2006cited by this paper
• Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas

  2005cited by this paper
• Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment

  2005cited by this paper
• Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

  2005cited by this paper
• Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin

  2005cited by this paper
• DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

  2005cited by this paper
• Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy.

  2005cited by this paper
• China approves first gene therapy

  2004cited by this paper
• Targeting the p53–MDM2 interaction to treat cancer

  2004cited by this paper
• Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.

  2004cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.

  2004cited by this paper
• Small molecules that reactivate mutant p53.

  2003cited by this paper
• Decision making by p53: life, death and cancer

  2003cited by this paper
• Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival.

  2003cited by this paper
• Radiation Enhances the Anti-tumor Effects of Vaccinia-p53 Gene Therapy in Glioma

  2003cited by this paper
• Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results.

  2003cited by this paper
• p53 Inhibitor Pifithrin α Can Suppress Heat Shock and Glucocorticoid Signaling Pathways*

  2003cited by this paper
• Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.

  2003cited by this paper
• Pifithrin-α supresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis

  2003cited by this paper
• Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives.

  2003cited by this paper
• Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants.

  2003cited by this paper
• Replication of an E1B 55-Kilodalton Protein-Deficient Adenovirus (ONYX-015) Is Restored by Gain-of-Function Rather than Loss-of-Function p53 Mutants

  2003cited by this paper
• Replication of an E 1 B 55-Kilodalton Protein-Deficient Adenovirus ( ONYX-015 ) Is Restored by Gain-of-Function Rather than Loss-of-Function p 53 Mutants

  2003cited by this paper
• TP53 and mutations in human cancer.

  2003cited by this paper
• INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.

  2003cited by this paper
• A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.

  2003cited by this paper
• Hepatitis B virus X protein sensitizes hepatocellular carcinoma cells to cytolysis induced by E1B-deleted adenovirus through the disruption of p53 function.

  2003cited by this paper
• Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.

  2003cited by this paper
• Inhibition of p53 protects liver tissue against endotoxin‐induced apoptotic and necrotic cell death

  2003cited by this paper
• Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis

  2003cited by this paper
• An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.

  2003cited by this paper
• Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics

  2003cited by this paper
• ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells.

  2003cited by this paper
• Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts

  2003cited by this paper
• Why did p53 gene therapy fail in ovarian cancer?

  2003cited by this paper
• Pifithrin‐α promotes p53‐mediated apoptosis in JB6 cells

  2003cited by this paper
• Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer.

  2003cited by this paper
• p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways.

  2003cited by this paper
• Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis.

  2003cited by this paper
• Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer

  2003cited by this paper
• Radical causes of cancer

  2003cited by this paper
• Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients

  2003cited by this paper
• Pifithrin-alpha promotes p53-mediated apoptosis in JB6 cells.

  2003cited by this paper
• Evidence that Replication of the Antitumor Adenovirus ONYX-015 Is Not Controlled by the p53 and p14ARF Tumor Suppressor Genes

  2002cited by this paper
• A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer

  2002cited by this paper
• Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500

  2002cited by this paper
• Acceleration of Cutaneous Wound Healing by Transient p53 Inhibition

  2002cited by this paper
• Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.

  2002cited by this paper
• The IARC TP53 database: New online mutation analysis and recommendations to users

  2002cited by this paper
• Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.

  2002cited by this paper
• Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells.

  2002cited by this paper
• Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas

  2002cited by this paper
• Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.

  2002cited by this paper
• Successful Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients With Bladder Cancer by Intravesical Vector Instillation

  2002cited by this paper
• Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database.

  2002cited by this paper
• Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

  2002cited by this paper
• Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand.

  2001cited by this paper
• Transcriptional targeting for ovarian cancer gene therapy.

  2001cited by this paper
• Combinatory anti-tumor effects of electroporation-mediated chemotherapy and wild-type p53 gene transfer to human esophageal cancer cells.

  2001cited by this paper
• Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

  2001cited by this paper
• Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

  2001cited by this paper
• Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity

  2001cited by this paper
• Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector.

  2001cited by this paper
• Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.

  2001cited by this paper
• Single-chain antibody against the common epitope of mutant p53: isolation and intracytosolic expression in mammalian cells.

  2001cited by this paper
• Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphavbeta3.

  2001cited by this paper
• Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

  2001cited by this paper
• Genotoxic and non-genotoxic pathways of p53 induction.

  2001cited by this paper
• Adenoviral Transduction Efficiency of Ovarian Cancer Cells Can Be Limited by Loss of Integrin β3 Subunit Expression and Increased by Reconstitution of Integrin αvβ3

  2001cited by this paper
• Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv

  2001cited by this paper
• The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth.

  2001cited by this paper
• A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.

  2000cited by this paper
• Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015)

  2000cited by this paper
• Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated P53 gene transfer in human bladder cancer model.

  2000cited by this paper
• A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

  2000cited by this paper
• Evaluation of combined vaccinia virus–mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model

  2000cited by this paper
• Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors

  2000cited by this paper
• Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity

  2000cited by this paper
• Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells.

  2000cited by this paper
• Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

  2000cited by this paper
• Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection.

  2000cited by this paper
• Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer.

  2000cited by this paper
• The role of p53-target genes in human cancer.

  2000cited by this paper
• Surfing the p53 network

  2000cited by this paper
• Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene.

  2000cited by this paper
• Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer.

  2000cited by this paper
• Cancer gene therapy mediated by CTS1, a p53 derivative: Advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2

  2000cited by this paper
• Objective responses from adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioalveolar cell lung carcinoma (BAC)

  2000cited by this paper
• Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments

  1999cited by this paper
• Polyamine Analogue Induction of the p 53-p 21 WAF 1 / CIP 1-Rb Pathway and G 1 Arrest in Human Melanoma Cells 1

  1999cited by this paper
• Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions

  1999cited by this paper
• Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer.

  1999cited by this paper
• Infectivity and expression of the early adenovirus proteins are important regulators of wild-type and ΔE1B adenovirus replication in human cells

  1999cited by this paper
• Polyamine depletion arrests cell cycle and induces inhibitors p21(Waf1/Cip1), p27(Kip1), and p53 in IEC-6 cells.

  1999cited by this paper
• Polyamine analogue induction of the p53-p21WAF1/CIP1-Rb pathway and G1 arrest in human melanoma cells.

  1999cited by this paper
• A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.

  1999cited by this paper
• Pharmacological rescue of mutant p53 conformation and function.

  1999cited by this paper
• A Chemical Inhibitor of p 53 That Protects Mice from the Side Effects of Cancer Therapy

  1999cited by this paper
• Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma.

  1998cited by this paper

• Tangeretin induces apoptosis and cell cycle arrest in thyroid cancer cells

  2025cites this paper
• Wip1 phosphatase activator QGC-8-52 specifically sensitizes p53-negative cancer cells to chemotherapy while protecting normal cells.

  2024cites this paper
• Trehalose and its diverse biological potential.

  2023cites this paper
• Study of MDM2 as Prognostic Biomarker in Brain-LGG Cancer and Bioactive Phytochemicals Inhibit the p53-MDM2 Pathway: A Computational Drug Development Approach

  2023influential citation
• Multifaceted functions of RPS27a: An unconventional ribosomal protein

  2022influential citation
• Synthesis of Copolymers Polyethyleneimine-co-Polyphenylalanine as Gene and Drug Codelivery Carrier.

  2021cites this paper
• Methylation as a critical epigenetic process during tumor progressions among Iranian population: an overview

  2021cites this paper
• Methylation as a critical epigenetic process during tumor progressions among Iranian population: an overview

  2021cites this paper
• Endoplasmic Reticulum Stress and Autophagy in Cancer

  2020cites this paper
• Bayesian Structure Learning in Multilayered Genomic Networks

  2020cites this paper
• Novel Mannich base 3FB3FA8H induces apoptosis by upregulating P53 pathway in neuroblastoma cells

  2020cites this paper
• Evaluation of Apoptosis Induction by Newcastle Disease Virus LaSota Strain in Human Breast Carcinoma Cells.

  2020cites this paper
• Head and Neck Cancer

  2020cites this paper
• Oxalomalate reduces tumor progression in melanoma via ROS-dependent proapoptotic and antiangiogenic effects.

  2019cites this paper
• Nutlin3a-Loaded Nanoparticles Show Enhanced Apoptotic Activity on Prostate Cancer Cells

  2019cites this paper
• Nicotine Promotes Human Papillomavirus (HPV)-Immortalized Cervical Epithelial Cells (H8) Proliferation by Activating RPS27a-Mdm2-P53 Pathway In Vitro

  2018cites this paper
• Involvement of RPL11 in the enhancement of P53 stability by a podophyllum derivative, a topoisomerase II inhibitor

  2018cites this paper
• A novel, semi-synthetic diterpenoid 16(R and S)-phenylamino-cleroda-3,13(14), Z-dien-15,16 olide (PGEA-AN) inhibits the growth and cell survival of human neuroblastoma cell line SH-SY5Y by modulating P53 pathway

  2018cites this paper
• Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents

  2018cites this paper
• Targeting the apoptotic Mcl-1-PUMA interface with a dual-acting compound.

  2017cites this paper
• Structure and activity studies of tyrosinases and related proteins

  2017cites this paper
• Targeting the apoptotic Mcl-1-PUMA interface with a dual-acting compound

  2017cites this paper
• Tumor suppressor protein p53 exerts negative transcriptional regulation on human sodium iodide symporter gene expression in breast cancer

  2017cites this paper
• OncoKB: A Precision Oncology Knowledge Base.

  2017cites this paper
• P-3F, a microtubule polymerization inhibitor enhances P53 stability through the change in localization of RPS27a.

  2017cites this paper
• Valproic Acid as a Promising Co-Treatment With Paclitaxel and Doxorubicin in Different Ovarian Carcinoma Cell Lines

  2016cites this paper
• Evaluation and Elucidation Studies of Natural Aglycones for Anticancer Potential using Apoptosis-Related Markers: An In silico Study

  2016cites this paper
• Discovery of Novel (Imidazo[1,2-a]pyrazin-6-yl)ureas as Antiproliferative Agents Targeting P53 in Non-small Cell Lung Cancer Cell Lines.

  2016cites this paper
• Torilis japonica extract-generated intracellular ROS induces apoptosis by reducing the mitochondrial membrane potential via regulation of the AMPK-p38 MAPK signaling pathway in HCT116 colon cancer.

  2016cites this paper
• Pharmacokinetics and Pharmacodynamics of Peptide and Protein Drugs

  2016cites this paper
• TP 53 transcription factor for the NEDD 9 / HEF 1 / CasL gene : potential targets in Non-Small Cell Lung Cancer treatment

  2016cites this paper
• Rompiendo la inmunotolerancia en el entorno tumoral mediante el uso de vacunas oncolíticas

  2016cites this paper
• PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms

  2015cites this paper
• TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment

  2015cites this paper
• Codelivery of antitumor drug and gene by a pH-sensitive charge-conversion system.

  2015cites this paper
• ONCOLYTIC VIROTHERAPY IN CANCER

  2015cites this paper
• Изучение прогностической значимости маркера апоптоза гена р53 и васкулоэндотелиального фактора роста при оценке клинического течения ангиофибромы носоглотки

  2015cites this paper
• (S)-Goniothalamin induces DNA damage, apoptosis, and decrease in BIRC5 messenger RNA levels in NCI-H460 cells

  2014cites this paper
• POLYMERIC NANOPARTICLE MEDIATED TARGETED DRUG DELIVERY TO CANCER CELLS

  2014cites this paper
• Small molecule compounds targeting the p53 pathway: are we finally making progress?

  2014cites this paper
• Novel DNA damage induced pathways to cancer : the role of PCAF histone acetyltransferase

  2014cites this paper
• Synergistic anti-tumor effects of nitroreductase mutants and p53.

  2014cites this paper
• Molecular Signatures in Urologic Tumors

  2013cites this paper
• Soluble HER-2 in Patients with Head and Neck Squamous Cell Carcinoma

  2013cites this paper
• Efficacy of Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural or Peritoneal Effusions

  2013cites this paper
• Regulation of ASPP2 Interaction with p53 Core Domain by an Intramolecular Autoinhibitory Mechanism

  2013cites this paper
• Targeting the p53 pathway.

  2013influential citation
• Cardiac Glycosides and Anticancer Activity

  2013cites this paper
• Identification of human guanylate-binding protein 1 gene (hGBP1) as a direct transcriptional target gene of p53.

  2013cites this paper
• Wip1 sensitizes p53-negative tumors to apoptosis by regulating the Bax/Bcl-xL ratio

  2012cites this paper
• Inhibitory Effects of Trehalose on Malignant Melanoma Cell Growth: Implications for a Novel Topical Anticancer Agent on the Ocular Surface

  2012cites this paper
• New Insights into p53 Signaling and Cancer Cell Response to DNA Damage: Implications for Cancer Therapy

  2012cites this paper
• Small molecule agents targeting the p53‐MDM2 pathway for cancer therapy

  2012cites this paper
• Restoring p53 Function: Novel Anticancer Approaches for an Old Foe

  2012influential citation
• Oncolytic viruses & their specific targeting to tumour cells

  2012cites this paper
• A Cell-Based High-Throughput Assay for the Screening of Small-Molecule Inhibitors of p53–MDM2 Interaction

  2011cites this paper
• Expression of c-erb B 2 and p 53 in Curatively Resected Gastric Cancer : Correlation with Clinicopathologic Features and Prognosis

  2011cites this paper
• Non-genotoxic p53-activators and their significance as antitumor therapy of future.

  2011cites this paper
• Expression of c-erbB2 and p53 in Curatively Resected Gastric Cancer: Correlation with Clinicopathologic Features and Prognosis.

  2011cites this paper
• Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53

  2011cites this paper
• Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma.

  2011cites this paper
• TP53 Arg72Pro Gene Polymorphism in Patients with Malignant Head and Neck Tumors

  2011cites this paper
• Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents

  2011cites this paper
• UNIVERSIDADE DA BEIRA INTERIOR FACULDADE DE CIÊNCIAS DA SAÚDE Master Degree Thesis in Biomedical Sciences DEVELOPMENT OF A NEW DRUG DELIVERY SYSTEM FOR FUTURE APPLICATION IN CANCER THERAPY

  2010influential citation
• Brush-shaped polycation with poly(ethylenimine)-b-poly(ethylene glycol) side chains as highly efficient gene delivery vector.

  2010cites this paper
• Synergistic gastric cancer inhibition by chemogenetherapy with recombinant human adenovirus p53 and epirubicin: an in vitro and in vivo study.

  2010cites this paper
• Focal adhesion kinase and p53 signal transduction pathways in cancer.

  2010cites this paper
• p53-based anti-cancer therapies: An empty promise?

  2010influential citation
• Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis.

  2010cites this paper
• Targeting p53 for Novel Anticancer Therapy.

  2010cites this paper
• Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells.

  2010cites this paper
• Análise de mutações no gene TP53 em casos de câncer de mama e estudo da proteína p53 mutante: aspectos fisiopatológicos do tumor

  2010cites this paper
• Focal Adhesion Kinase with the Interacting Proteins and Signaling in Cancer

  2010cites this paper
• Targeting p53 for Novel Anticancer Therapy 1

  2010cites this paper
• radon-induites chez le rat

  2009cites this paper
• Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition.

  2009cites this paper
• Apoptosis in Colorectal Tumorigenesis and Chemotherapy

  2009cites this paper
• Award Number: W81XWH-08-1-0539 TITLE: Chemoprevention by elimination of cancer-prone, mutant p53-containing breast cells

  2009cites this paper
• Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors.

  2009cites this paper
• Association Between MGMT Promoter Hypermethylation and p53 Mutation in Glioblastoma

  2009cites this paper
• Involvement of p53 in oroxylin A‐induced apoptosis in cancer cells

  2009cites this paper
• Disruption of estrogen receptor α-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy

  2009cites this paper
• Recent advances in validating MDM2 as a cancer target.

  2009cites this paper
• The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death

  2009cites this paper
• Finding fractal patterns in molecular interaction networks: a case study in Alzheimer's disease

  2009cites this paper
• Apoptosis in Carcinogenesis and Chemotherapy

  2009cites this paper
• Caspase activity modulators as anticancer agents.

  2008cites this paper
• Regulation of apoptosis during treatment and resistance development in tumour cells

  2008cites this paper
• Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

  2008cites this paper
• Caractérisation moléculaire de tumeurs pulmonaires radon-induites chez le rat

  2008cites this paper
• Zinc metalloproteins as medicinal targets.

  2008cites this paper
• МУТаЦИИ в ГЕНЕ-СУПРЕССоРЕ ТР53 И ИХ СвяЗЬ С оС оБЕННоСТ яМИ КЛИНИЧЕСКоГ о ТЕЧЕНИя Р аКа Мо ЛоЧНоЙ ЖЕЛЕЗЫ

  2008cites this paper
• Helicases as prospective targets for anti-cancer therapy.

  2008cites this paper
• An investigation of p53’s differential activation of cell cycle arrest and apoptosis

  2008cites this paper
• Therapeutic Reactivation of the p53 Tumor Suppressor Protein in HPV-Positive Cervical Cancer Cells by the Creosote Bush Lignan 3’-O-Methyl-Nordihydroguaiaretic Acid

  2007cites this paper
• Viruses as anticancer drugs.

  2007cites this paper
• Focal adhesion kinase and p53 signaling in cancer cells.

  2007cites this paper
• The molecular genetics of breast cancer and targeted therapy

  2007cites this paper
• On the ubiquitination and protein-protein interactions of p53

  2007cites this paper
• Prognostic significance of p53 gene mutations and protein overexpression in localized gastrointestinal stromal tumours

  2007cites this paper